The United States Patent Office has issued to Biosafe, Inc. a composition of matter patent on the siloxane polymer that is the keystone of the company’s proprietary antimicrobial technology. The chemistry underlying the antimicrobial causes it to molecularly bond to the treated surfaces of film, sheet, molded plastics, non-wovens, metals, wood and other substances, enabling it to resist leaching or migration and providing long-lasting protection against bacteria, mold, mildew, and fungi.
In addition, the antimicrobial punctures and ruptures the cell walls of target microbes rather than leaching into the cells. This action prevents the microorganisms from mutating and adapting to the antimicrobial treatment, becoming so-called “super-bugs” that have become a source of cross-infection in hospitals and clinics.
In medical products, Biosafe polymer could be used to combat harmful bacteria and viruses commonly encountered in clinical settings. Medical textiles treated with the polymer have demonstrated a 99.999 percent reduction of certain micro-organisms within five minutes. Among the microbes involved in tests required for submission to the FDA were MRSA, VRE, Influenza A, and staphylococcus aureaus.
The additive also costs less to use than conventional silver-ion antimicrobials, which must be used at much higher concentration levels, stated company officials.